Research ArticleOpen AccessGoogle Scholar indexed
Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer
Department of Internal Medicine, University of California San Francisco-Fresno, Fresno, CA, USA
Wayne State University School of Medicine, Detroit, MI, USA
Division of Hematology/Oncology, University of California San Francisco-Fresno, Fresno, CA, USA
- 1 Department of Internal Medicine, University of California San Francisco-Fresno, Fresno, CA, USA
- 2 Wayne State University School of Medicine, Detroit, MI, USA
- 3 Division of Hematology/Oncology, University of California San Francisco-Fresno, Fresno, CA, USA
Journal of Cancer Therapy·Volume 08 (2017)·Pages 1149–1159·Published 12 December 2017·DOI10.4236/jct.2017.813098
Copy link · social · email
Abstract
Androgen deprivation therapy has been the mainstay of treatment for management of metastatic hormone sensitive prostate cancer. Recently conducted randomized controlled trials with docetaxel based chemotherapy have shed light on benefit of early use chemotherapy for hormone sensitive prostate cancer. In this review, we aim to comprehensively describe recent trials which are changing the paradigm in support of up front use of docetaxel based chemotherapy for metastatic hormone sensitive prostate cancer.
KeywordsMetastatic Prostate CancerHormone Sensitive Disease
- Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
- Huggins, C. and Hodges, C.V. (1972) Studies on Prostatic Cancer. I. The Effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians, 22, 232-240. https://doi.org/10.3322/canjclin.22.4.232
- Nussey, S. and Whitehead, S. (2001) Endocrinology: An Integrated Approach. BIOS Scientific Publishers BIOS Scientific Publishers Limited, Oxford. https://doi.org/10.4324/9780203450437
- Karantanos, T., Corn, P.G. and Thompson, T.C. (2013) Prostate Cancer Progression after Androgen Deprivation Therapy: Mechanisms of Castrate Resistance and Novel Therapeutic Approaches. Oncogene, 32, 5501-5511. https://doi.org/10.1038/onc.2013.206
- Attar, R.M., Takimoto, C.H. and Gottardis, M.M. (2009) Castration-Resistant Prostate Cancer: Locking up the Molecular Escape Routes. Clinical Cancer Research, 15, 3251-3255. https://doi.org/10.1158/1078-0432.CCR-08-1171
- Maughan, B.L. and Antonarakis, E.S. (2015) Androgen Pathway Resistance in Prostate Cancer and Therapeutic Implications. Expert Opinion on Pharmacotherapy, 16, 1521-1537. https://doi.org/10.1517/14656566.2015.1055249
- Hoang, D.T., et al. (2017) Androgen Receptor-Dependent and -Independent Mechanisms Driving Prostate Cancer Progression: Opportunities for Therapeutic Targeting from Multiple Angles. Oncotarget, 8, 3724-3745.
- Montgomery, R.B., et al. (2008) Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth. Cancer Research, 68, 4447-4454. https://doi.org/10.1158/0008-5472.CAN-08-0249
- Mohler, J.L., et al. (2004) The Androgen Axis in Recurrent Prostate Cancer. Clinical Cancer Research, 10, 440-448. https://doi.org/10.1158/1078-0432.CCR-1146-03
- Harris, W.P., et al. (2009) Androgen Deprivation Therapy: Progress in Understanding Mechanisms of Resistance and Optimizing Androgen Depletion. Nature Clinical Practice Urology, 6, 76-85. https://doi.org/10.1038/ncpuro1296
- Koochekpour, S. (2010) Androgen Receptor Signaling and Mutations in Prostate Cancer. Asian Journal of Andrology, 12, 639-657. https://doi.org/10.1038/aja.2010.89
- Hernandez-Aya, L.F. and Hussain, M. (2015) Why Chemotherapy Should Be Given Early for Men with Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book, e263-e269. https://doi.org/10.14694/EdBook_AM.2015.35.e263